However, other molecular features such as p53 alterations [18], HER2 overexpression [19], and MYC alteration [20] have also failed to be prognostic in most bladder cancer studies although they are known cancer-drivers and related to patient outcome in many other tumor entities [21, 22]. This evidence concerns the gene ERBB2 and urinary bladder cancer.